Difference between revisions of "CT Angiography Biomarker Ctte"
Jump to navigation
Jump to search
m (→Meetings) |
m |
||
| Line 1: | Line 1: | ||
| − | '''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT | + | '''Co-chairs''': Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT |
'''RSNA Staff Support''': Julie Lisiecki | '''RSNA Staff Support''': Julie Lisiecki | ||
| Line 10: | Line 10: | ||
| − | *[[Media: 2022 10 25 QIBA CT | + | *[[Media:2022 10 25 QIBA CT Angiography FINAL.pdf| October 25, 2022]] |
| − | *[[Media: 2022 10 11 QIBA CT | + | *[[Media:2022 10 11 QIBA CT Angiography FINAL.pdf| October 11, 2022]] |
| − | *[[Media: 2022 09 27 QIBA CT | + | *[[Media:2022 09 27 QIBA CT Angiography FINAL.pdf| September 27, 2022]] |
| − | *[[Media: 2022 09 13 QIBA CT | + | *[[Media:2022 09 13 QIBA CT Angiography FINAL-2.pdf| September 13, 2022]] |
| − | *[[Media: 2022 08 30 QIBA CT | + | *[[Media:2022 08 30 QIBA CT Angiography FINAL.pdf| August 30, 2022]] |
| − | *[[Media: 2022 08 16 QIBA CT | + | *[[Media:2022 08 16 QIBA CT Angiography FINAL.pdf| August 16, 2022]] |
| − | *[[Media: 2020 06 16 QIBA CT | + | *[[Media:2020 06 16 QIBA CT Angiography FINAL.pdf| June 16, 2020]] |
| Line 30: | Line 30: | ||
==Profile Development== | ==Profile Development== | ||
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-11-27-full.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-11-27.PDF| QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)]] |
| − | *[[Media:CTA Comments 2019-11-27.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | + | *[[Media:CTA Comments 2019-11-27.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-10-30.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media:CTA Comments 2019-10-30.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | + | *[[Media:CTA Comments 2019-10-30.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-09-09b.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media:CTA Comments 2019-09-09.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | + | *[[Media:CTA Comments 2019-09-09.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-08-26.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media:CTA Comments 2019-08-26.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | + | *[[Media:CTA Comments 2019-08-26.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-08-12.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media:CTA Comments 2019-08-12.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | + | *[[Media:CTA Comments 2019-08-12.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-07-29.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media:CTA Comments 2019-07-29.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | + | *[[Media:CTA Comments 2019-07-29.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-02-26.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media: | + | *[[Media:Atherosclerosis Biomarkers Profile 2019-02-11.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media: | + | *[[Media:2019 01-31 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media: | + | *[[Media:2019 01-14 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] |
| − | *[[Media: | + | *[[Media:2018 12-17 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]] |
'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]''''' | '''''[[Atherosclerosis Biomarkers Profile Draft Archive]]''''' | ||
| Line 59: | Line 59: | ||
==Reference Materials== | ==Reference Materials== | ||
| − | *[[Media:Biomarkers Selection Criteria.pdf | QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF) | + | *[[Media:Biomarkers Selection Criteria.pdf| QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF) |
==Conformance Materials== | ==Conformance Materials== | ||
Revision as of 14:38, 24 October 2022
Co-chairs: Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
RSNA Staff Support: Julie Lisiecki
Meetings
Recent Call Summaries:
- October 25, 2022
- October 11, 2022
- September 27, 2022
- September 13, 2022
- August 30, 2022
- August 16, 2022
- June 16, 2020
CT Angiography Call Summaries Archive
Project Snapshot - CT Angiography
The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).
Excerpt from the biomarker committee submission form:
The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
Profile Development
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
- QIBA Atherosclerosis Biomarkers Profile Draft
Atherosclerosis Biomarkers Profile Draft Archive
Groundwork Projects
Reference Materials
- QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler} March 27, 2018 (PDF)